210 related articles for article (PubMed ID: 25466846)
1. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio.
Moore GW; de Jager N; Cutler JA
Thromb Res; 2015 Jan; 135(1):161-6. PubMed ID: 25466846
[TBL] [Abstract][Full Text] [Related]
2. Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia.
Orlando C; Heylen O; Lissens W; Jochmans K
Thromb Res; 2015 Jun; 135(6):1179-85. PubMed ID: 25837307
[TBL] [Abstract][Full Text] [Related]
3. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
[TBL] [Abstract][Full Text] [Related]
4. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency.
Kovács B; Bereczky Z; Oláh Z; Gindele R; Kerényi A; Selmeczi A; Boda Z; Muszbek L
Am J Clin Pathol; 2013 Nov; 140(5):675-9. PubMed ID: 24124146
[TBL] [Abstract][Full Text] [Related]
5. Great discrepancy in antithrombin activity measured using five commercially available functional assays.
Javela K; Engelbarth S; Hiltunen L; Mustonen P; Puurunen M
Thromb Res; 2013 Jul; 132(1):132-7. PubMed ID: 23768451
[TBL] [Abstract][Full Text] [Related]
6. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
[TBL] [Abstract][Full Text] [Related]
7. The phenotypic and genetic assessment of antithrombin deficiency.
Cooper PC; Coath F; Daly ME; Makris M
Int J Lab Hematol; 2011 Jun; 33(3):227-37. PubMed ID: 21401902
[TBL] [Abstract][Full Text] [Related]
8. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin.
Hepner M; Karlaftis V
Methods Mol Biol; 2013; 992():355-64. PubMed ID: 23546728
[TBL] [Abstract][Full Text] [Related]
10. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations.
Aguila S; Navarro-Fernández J; Bohdan N; Gutiérrez-Gallego R; de la Morena-Barrio ME; Vicente V; Corral J; Martínez-Martínez I
J Thromb Haemost; 2014 Jul; 12(7):1131-40. PubMed ID: 24824609
[TBL] [Abstract][Full Text] [Related]
11. Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin.
Izaguirre G; Swanson R; Raja SM; Rezaie AR; Olson ST
J Biol Chem; 2007 Nov; 282(46):33609-33622. PubMed ID: 17875649
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
[TBL] [Abstract][Full Text] [Related]
13. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin deficiency in three Japanese families: one novel and two reported point mutations in the antithrombin gene.
Maruyama K; Morishita E; Karato M; Kadono T; Sekiya A; Goto Y; Sato T; Nomoto H; Omi W; Tsuzura S; Imai H; Asakura H; Ohtake S; Nakao S
Thromb Res; 2013 Aug; 132(2):e118-23. PubMed ID: 23809926
[TBL] [Abstract][Full Text] [Related]
15. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
16. The Homozygous Type II Antithrombin Deficient Pregnant Woman Monitored by Thrombin Generation Assay.
Malikova I; Husakova M; Bilkova J; Brzezkova R; Hrachovinova I; Kvasnicka T
Clin Lab; 2023 Oct; 69(10):. PubMed ID: 37844053
[TBL] [Abstract][Full Text] [Related]
17. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
Rezaie AR
Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
[TBL] [Abstract][Full Text] [Related]
18. Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: phenotype analysis in a large cohort.
Gindele R; Oláh Z; Ilonczai P; Speker M; Udvari Á; Selmeczi A; Pfliegler G; Marján E; Kovács B; Boda Z; Muszbek L; Bereczky Z
J Thromb Haemost; 2016 Apr; 14(4):704-15. PubMed ID: 26748602
[TBL] [Abstract][Full Text] [Related]
19. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
20. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence.
Sanchez J; Elgue G; Riesenfeld J; Olsson P
J Biomed Mater Res; 1995 May; 29(5):655-61. PubMed ID: 7622551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
